2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
…, A Sepriano, A Regel, A Ciurea… - Annals of the …, 2017 - ard.bmj.com
To update and integrate the recommendations for ankylosing spondylitis and the recommendations
for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA…
for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA…
[HTML][HTML] Subarachnoid hemorrhage and cerebral vasospasm–literature review
AV Ciurea, C Palade, D Voinescu… - Journal of medicine and …, 2013 - ncbi.nlm.nih.gov
Subarachnoid hemorrhage represents a serious disease with high mortality and morbidity.
Two important areas are becoming the central research interest of subarachnoid hemorrhage…
Two important areas are becoming the central research interest of subarachnoid hemorrhage…
[HTML][HTML] Genetics of craniosynostosis: review of the literature
AV Ciurea, C Toader - Journal of medicine and life, 2009 - ncbi.nlm.nih.gov
Craniosynostosis represents a defection of the skull caused by early fusion of one or more
cranial sutures. The shape alteration of the cranial vault varies, depending on the fused …
cranial sutures. The shape alteration of the cranial vault varies, depending on the fused …
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
…, B Boteva, A Bremander, P Carron, A Ciurea… - Annals of the …, 2023 - ard.bmj.com
Objectives To update the Assessment of SpondyloArthritis international Society (ASAS)-EULAR
recommendations for the management of axial spondyloarthritis (axSpA). Methods …
recommendations for the management of axial spondyloarthritis (axSpA). Methods …
B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to …
Objective Patients with rheumatoid arthritis (RA) in whom the response to anti–tumor
necrosis factor (anti‐TNF) therapy is inadequate have several therapeutic options, such as …
necrosis factor (anti‐TNF) therapy is inadequate have several therapeutic options, such as …
[HTML][HTML] Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course
…, E Bernasconi, A Rauch, A Manzo, A Ciurea… - Nature …, 2023 - nature.com
Infection with severe acute respiratory syndrome coronavirus 2 associates with diverse
symptoms, which can persist for months. While antiviral antibodies are protective, those targeting …
symptoms, which can persist for months. While antiviral antibodies are protective, those targeting …
TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort
…, RBM Landewé, D van der Heijde, A Ciurea - Annals of the …, 2018 - ard.bmj.com
Objectives To analyse the impact of tumour necrosis factor inhibitors (TNFis) on spinal
radiographic progression in ankylosing spondylitis (AS). Methods Patients with AS in the Swiss …
radiographic progression in ankylosing spondylitis (AS). Methods Patients with AS in the Swiss …
[HTML][HTML] Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections
L Hunziker, M Recher, AJ Macpherson, A Ciurea… - Nature …, 2003 - nature.com
Polyclonal hypergammaglobulinemia is a characteristic of chronic inflammatory conditions,
including persisting viral infections and autoimmune diseases. Here we have studied …
including persisting viral infections and autoimmune diseases. Here we have studied …
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous …
Background: Patients with rheumatoid arthritis (RA) with an inadequate response to TNF
antagonists (aTNFs) may switch to an alternative aTNF or start treatment from a different class …
antagonists (aTNFs) may switch to an alternative aTNF or start treatment from a different class …
Comparison of drug retention rates and causes of drug discontinuation between anti–tumor necrosis factor agents in rheumatoid arthritis
SMD Pan, S Dehler, A Ciurea… - Arthritis Care & …, 2009 - Wiley Online Library
Objective Tumor necrosis factor (TNF) inhibitors have revolutionized the treatment of severe
rheumatoid arthritis (RA), yet drug discontinuation is common. The aim of this study was to …
rheumatoid arthritis (RA), yet drug discontinuation is common. The aim of this study was to …